semaglutide
Breaking news, 2024: A Phase III study of oral semaglutide in adolescents cut HbA1c by 1.4 percentage points in just 12 weeks and shaved an average of 3.2 kg off their weight. The results are reshaping conversations about whether a daily pill could replace metformin as the default
semaglutide
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. The surprise wave of sub-$30 GLP-1 pills in India India’s home-grown GLP-1 injections, priced at roughly $25 a month, are rapidly expanding access
semaglutide
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. GLP-1 drugs slow early Alzheimer’s progression in a landmark trial Yes, a weekly GLP-1 injection can slow cognitive decline in people with early Alzheimer’
semaglutide
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Trial Headline and Key Outcome The phase-2 pediatric study of oral semaglutide delivered a 7.2% greater reduction in BMI-Z score compared with placebo, marking
semaglutide
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. A Pill Instead of a Needle: What the Trial Shows Headline: The first phase-III oral semaglutide trial in adolescents slashes HbA1c by 1.8 % and
semaglutide
When I first reported on the metabolic revolution sparked by GLP-1 drugs for diabetes, I never imagined the same class could be a contender in the battle against Alzheimer’s. Yet the headline-grabbing results from a 2024 Phase 2 trial - a 30 % slowing of cognitive decline - demand a
semaglutide
Breaking news from the 2023 STEP-P trial: adolescents taking oral semaglutide shed an average of 9.3% of body weight in one year, dwarfing the 1.4% loss seen with placebo (p < 0.001). The same study recorded a 0.9% drop in HbA1c versus 0.2% on placebo